ONTX - Onconova Therapeutics Inc Stock Price, Fair Value and News

$5.02-0.32 (-5.99%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ONTX Price Action

Last 7 days

-2.5%

Last 30 days

-16.7%

Last 90 days

1228.6%

Trailing 12 Months

520%

ONTX RSI Chart

ONTX Valuation

Market Cap

15.2M

Price/Earnings (Trailing)

-0.11

Price/Sales (Trailing)

67.2

EV/EBITDA

-0.71

Price/Free Cashflow

-0.5

ONTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ONTX Fundamentals

ONTX Revenue

Revenue (TTM)

226.0K

ONTX Earnings

Earnings (TTM)

-140.8M

Earnings Growth (Yr)

-78.84%

Earnings Growth (Qtr)

93.12%

ONTX Profitability

EBT Margin

-7151.77%

Return on Equity

6.9K%

Return on Assets

-1.6K%

Free Cashflow Yield

-198.72%

ONTX Investor Care

Buy Backs (1Y)

85.59%

Diluted EPS (TTM)

-2.96

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	226.0K	226.0K	226.0K	0
2023	226.0K	226.0K	226.0K	226.0K
2022	226.0K	226.0K	226.0K	226.0K
2021	235.0K	236.0K	227.0K	226.0K
2020	2.2M	201.0K	204.0K	231.0K
2019	1.5M	1.7M	1.9M	2.2M
2018	1.1M	1.3M	1.3M	1.2M
2017	4.3M	2.4M	817.0K	787.0K
2016	12.8M	14.9M	15.0M	5.5M
2015	467.0K	465.0K	2.0M	11.5M
2014	4.1M	3.6M	2.6M	800.0K
2013	46.8M	47.5M	5.8M	4.8M
2012	12.7M	23.8M	35.0M	46.2M
2011	0	0	0	1.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Onconova Therapeutics Inc

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

CEO	Dr. Steven M. Fruchtman M.D.
WEBSITE	onconova.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	16

Onconova Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Onconova Therapeutics Inc? What does ONTX stand for in stocks?

ONTX is the stock ticker symbol of Onconova Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Onconova Therapeutics Inc (ONTX)?

As of Thu Dec 19 2024, market cap of Onconova Therapeutics Inc is 15.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ONTX stock?

You can check ONTX's fair value in chart for subscribers.

Is Onconova Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ONTX is over valued or under valued. Whether Onconova Therapeutics Inc is cheap or expensive depends on the assumptions which impact Onconova Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ONTX.

What is Onconova Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 19 2024, ONTX's PE ratio (Price to Earnings) is -0.11 and Price to Sales (PS) ratio is 67.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ONTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Onconova Therapeutics Inc's stock?

In the past 10 years, Onconova Therapeutics Inc has provided -0.53 (multiply by 100 for percentage) rate of return.